The South African government has unveiled an ambitious roadmap to secure the future of HIV prevention. By 2027, the state intends to facilitate generic Lenacapavir manufacturing within its borders. This move aims to address a critical supply deficit of the game-changing, twice-yearly injectable. Lenacapavir (LEN) is a potent pre-exposure prophylaxis (PrEP) agent. It was registered in South Africa in October…